ARTICLE | Company News
Pharmacyclics, Servier deal
October 20, 2014 7:00 AM UTC
The companies mutually terminated a 2009 deal granting Servier exclusive, ex-U.S. rights to develop and commercialize abexinostat. The histone deacetylase (HDAC) inhibitor has completed Phase II tria...